Vasopressin

Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. ( 1 )

Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol. Vasopressin Injection, USP 1 mL single dose vial is contraindicated in patients with known allergy or hypersensitivity to 8‑L-arginine vasopressin or chlorobutanol. ( 4 )

Can worsen cardiac function. ( 5.1 ) Reversible diabetes insipidus ( 5.2 )

5.1Worsening Cardiac Function

A decrease in cardiac index may be observed with the use of Vasopressin Injection, USP.

5.2Reversible Diabetes Insipidus

Patients may experience reversible diabetes insipidus, manifested by the development of polyuria, a dilute urine, and hypernatremia, after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status, and urine output after vasopressin discontinuation. Some patients may require readministration of vasopressin or administration of desmopressin to correct fluid and electrolyte shifts.

Pressor effects of catecholamines and Vasopressin Injection, USP are expected to be additive. ( 7.1 ) Indomethacin may prolong effects of Vasopressin Injection, USP. ( 7.2 ) Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response. ( 7.3 , 7.5 ) Co-administration of drugs causing diabetes insipidus may decrease the pressor response. ( 7.6 )

7.1Catecholamines Use

with catecholamines is expected to result in an additive effect on mean arterial blood pressure and other hemodynamic parameters. Hemodynamic monitoring is recommended; adjust the dose of vasopressin as needed.